These findings increase the interest for Gal-3 as a potential new target for therapeutic intervention to prevent obesity-associated cardiac lipotoxicity and subsequent mitochondrial dysfunction. Here, LGALS3 is linked to obesity due to melanocortin 4 receptor deficiency.